Publicacións en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (89)

2024

  1. Advanced fibrosis associated with non-alcoholic steatohepatitis (NASH) in Spain: results of a Delphi study

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 337-346

  2. Baiona's Consensus Statement for Fecal Incontinence. Spanish Association of Coloproctology

    Cirugia Espanola, Vol. 102, Núm. 3, pp. 158-173

  3. Combination of granulocyte–monocyte apheresis and tofacitinib: Multicentre and retrospective study

    Gastroenterologia y Hepatologia

  4. Combination of granulocyte–monocyte apheresis and ustekinumab: Multicentre and retrospective study

    Gastroenterologia y Hepatologia

  5. LiverAI: New tool in the landscape for liver health

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 6, pp. 646-648

  6. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615

  7. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics

  8. Recommendations for the future management of thrombocytopenia in patients with liver cirrhosis: A modified RAND/UCLA appropriateness method

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 1, pp. 32-50

  9. Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: Results from the ColHai registry

    Liver International

  10. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology

2023

  1. Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP

    Journal of Clinical Medicine, Vol. 12, Núm. 14

  2. Effectiveness and safety of once-daily tacrolimus formulations in de novo liver transplant recipients: The PRETHI study

    Clinical Transplantation, Vol. 37, Núm. 12

  3. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132

  4. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

  5. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study

    Alimentary Pharmacology and Therapeutics, Vol. 58, Núm. 1, pp. 60-70

  6. Severe congenital X-linked myopathy with excessive autophagy secondary to an apparently synonymous but pathogenic novel variant

    Neuromuscular Disorders, Vol. 33, Núm. 7, pp. 557-561

  7. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

    Digestive Diseases and Sciences, Vol. 68, Núm. 6, pp. 2731-2737

2022

  1. Abdominal normothermic regional perfusion in controlled donation after circulatory determination of death liver transplantation: Outcomes and risk factors for graft loss

    American Journal of Transplantation, Vol. 22, Núm. 4, pp. 1169-1181

  2. Autosomal recessive spinocerebellar ataxia SCAR8/ARCA1: First families detected in Spain

    Neurologia, Vol. 37, Núm. 4, pp. 257-262

  3. Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path toward the implementation of telemedicine in Spain?

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 697-705